Alligator Bioscience (ATORX.ST) Stock Analysis & AI Equity Report
Alligator Bioscience (ATORX.ST) overview
Alligator Bioscience (ATORX.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Alligator Bioscience reported revenue of SEK 0.5m and operating profit of SEK -122m; the year-end share price was 0.34 SEK and market capitalisation was SEK 9.3m. Alligator Bioscience is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Alligator Bioscience's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Alligator Bioscience
Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs for cancer treatment. Its portfolio includes mono- and bispecific antibodies, with mitazalimab as a lead program and HLX22 now a strategic focus. The company is headquartered in Lund, Sweden, and listed on Nasdaq Stockholm under the ticker ATORX.
Generate the Alligator Bioscience report
Alligator Bioscience is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Alligator Bioscience and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Alligator Bioscience
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.